Cell & Gene Therapy Catapult
A world-leading research facility in the heart of London
Based on the 12th floor of Guys Tower, within London’s Guys Hospital estate, the Cell & Gene Therapy Catapult provides specialist clinical and laboratory space to help companies and researchers all over the world transform early stage research into commercially viable and investable therapies.
Helping ideas become a reality
Established by Innovate UK, the catapult model is intended to support increased innovation by creating space for businesses and researchers to collaborate and problem solve. Each centre, which specialises in a different area of technology, provides access to expert technical capabilities and equipment that helps transform ideas from concept to reality.
Gleeds provided project management, cost management and CDMC services for the construction of this centre of excellence. The complexities of working in a live hospital environment, teamed with the access restrictions associated with working at height, involved complex stakeholder management.
Construction lasted 26 weeks and was delivered on time to allow occupation by the Catapult as intended. Our contribution to the successful delivery of the project was influential in Gleeds securing the commission for the Transport Systems Catapult in Milton Keynes.
Value engineering to achieve a striking design
Original designs for the space in Guy’s Tower lacked the energy and vibrancy the Catapult aspired to, so a specialist architect was brought on board to help create a space that would inspire collaboration and creative thinking.
This was achieved within budget by increasing design specification to key areas, and reducing the specification in non-critical areas. The result was a bespoke, eye catching design with only a moderate increase in cost.
The Gleeds team has played an invaluable role on the development of the Cell & Gene Therapy Catapult facility within Guy’s Hospital. Their dedication and support has ensured that we’ve been able to deliver a world class facility that will be instrumental in cementing the UK’s position as global leaders in the research and development of Cell & Gene Therapy technologies. John Topliss, Head of Property at Innovate UK